About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals acquires, develops and commercializes a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease. For more information, please visit our website at http://www.spectrumpharm.com.
Forward-looking statement -- This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially. These
statements include but are not limited to statements that relate to our
business and its future, Spectrum's ability to identify, acquire, develop
and commercialize its portfolio of drug candidates, the Company's promising
pipeline, that if approved, EOquin may help the many patients suffering
from non-invasive bladder cancer, that EOquin is expected to carry a low
risk of systemic toxicity, if any, the safety and efficacy of EOquin and
any statements that relate to the intent, belief, plans or expectations of
Spectrum or its management, or that are not a statement of historical fact.
Risks that could cause actual results to differ include the possibility
that our existing and new drug candidates, may not prove safe or effective,
the possibility that our existing and new drug candidates may not receive
approval from the FDA, and other regulatory age
|SOURCE Spectrum Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved